<?xml version="1.0" encoding="UTF-8"?>
<wcm:root xmlns:wcm="http://www.stellent.com/wcm-data/ns/8.0.0">
  <wcm:element name="MainContent">&lt;table cellspacing="0" cellpadding="2" border="0" summary="This table shows the date, time, and location of the meeting" style="WIDTH: 643px" id="schedule"&gt;     &lt;tbody&gt;         &lt;tr&gt;             &lt;th bgcolor="#cccccc" align="left" valign="top" style="WIDTH: 59px" id="a1"&gt;Center&lt;/th&gt;             &lt;th bgcolor="#cccccc" align="left" valign="top" style="WIDTH: 108px" id="a2"&gt;Date&lt;/th&gt;             &lt;th bgcolor="#cccccc" align="left" valign="top" style="WIDTH: 163px" id="a3"&gt;Time&lt;/th&gt;             &lt;th bgcolor="#cccccc" align="left" valign="top" style="WIDTH: 193px" id="a4"&gt;Location&lt;/th&gt;         &lt;/tr&gt;         &lt;tr&gt;             &lt;td valign="top" height="61" headers="a1" style="WIDTH: 59px"&gt;CDER&lt;/td&gt;             &lt;td valign="top" headers="a2" style="WIDTH: 108px"&gt;July 26, 2012&lt;/td&gt;             &lt;td valign="top" headers="a3" style="WIDTH: 163px"&gt;8:00 a.m. to 5:00 p.m.&lt;/td&gt;             &lt;td valign="top" headers="a4" style="WIDTH: 193px"&gt;FDA White Oak Campus&lt;br /&gt;             Building 31&lt;br /&gt;             The Great Room (Rm. 1503)&lt;br /&gt;             White Oak Conference Center&lt;br /&gt;             10903 New Hampshire Avenue&lt;br /&gt;             Silver Spring, Maryland&lt;/td&gt;         &lt;/tr&gt;     &lt;/tbody&gt; &lt;/table&gt; &lt;p&gt;&lt;strong&gt;Agenda&lt;/strong&gt;&lt;/p&gt; &lt;p&gt;During the morning session, the committee will discuss a supplement to biologics license application (BLA) 125156 for LUCENTIS (ranibizumab) injection by Genentech, Inc., for the treatment of diabetic macular edema (DME).  Ranibizumab injection is currently approved for the treatment of neovascular (wet) age-related macular degeneration (AMD) and macular edema following retinal vein occlusion (RVO).&lt;/p&gt; &lt;p&gt;During the afternoon session, the committee will discuss new biologics license application (BLA) 125422, ocriplasmin intravitreal injection (proposed tradename, Jetrea) by ThromboGenics, Inc., indicated for the treatment of symptomatic vitreomacular adhesions (sVMA) including macular hole.&lt;/p&gt; &lt;p&gt;&lt;strong&gt;Meeting Materials&lt;/strong&gt;&lt;/p&gt; &lt;p&gt;FDA intends to make background materials available to the public no later than 2 business days before the meeting.  If FDA is unable to post the background material on its Web site prior to the meeting, the background material will be made publicly available at the location of the advisory committee meeting, and the background material will be posted on FDA&amp;rsquo;s Web site after the meeting.&lt;/p&gt; &lt;p&gt;&lt;strong&gt;Background Material&lt;/strong&gt;&lt;/p&gt; &lt;ul&gt;     &lt;li&gt;&lt;a target="" href="[!--$wcmUrl('link','UCM280522')--]"&gt;2012 Meeting Materials, Dermatologic and Ophthalmic Drugs Advisory  Committee&lt;/a&gt;&lt;/li&gt; &lt;/ul&gt; &lt;p&gt;&lt;strong&gt;Public Participation Information&lt;/strong&gt;&lt;/p&gt; &lt;p&gt;Interested persons may present data, information, or views, orally or in  writing, on issues pending before the committee.&lt;/p&gt; &lt;ul type="disc"&gt;     &lt;li&gt;Written submissions may be made to the contact person on or before July 13, 2012.&lt;/li&gt;     &lt;li&gt;Oral presentations from the public will be scheduled between approximately 10 a.m. to  10:30 a.m. and 3 p.m. to 3:30 p.m. Those desiring to make formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before July 6, 2012.&lt;/li&gt; &lt;/ul&gt; &lt;p&gt;Time allotted for each presentation may be limited.  If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session.  The contact person will notify interested persons regarding their request to speak by July 9, 2012.&lt;/p&gt; &lt;p&gt;&lt;strong&gt;Webcast Information&lt;/strong&gt;&lt;/p&gt; &lt;p&gt;CDER plans to provide a free of charge, live webcast of the July 26, 2012, meeting of the Dermatologic and Ophthalmic Drugs Advisory Committee.  While CDER is working to make webcasts available to the public for all advisory committee meetings held at the White Oak campus, there are instances where the webcast transmission is not successful; staff will work to re-establish the transmission as soon as possible.  Further information regarding the webcast, including the web address for the webcast, will be made available at least 2 days in advance of the meeting at the following website: &lt;a target="" href="[!--$wcmUrl('link','UCM280522')--]"&gt;2012 Meeting Materials, Dermatologic and Ophthalmic Drugs Advisory  Committee&lt;/a&gt;.&lt;/p&gt; &lt;p&gt;CDER plans to post archived webcasts after the meeting, however, in cases where transmission was not successful, archived webcasts will not be available.&lt;/p&gt; &lt;p&gt;&lt;strong&gt;Contact Information&lt;/strong&gt;&lt;/p&gt; &lt;ul&gt;     &lt;li&gt;Yvette Waples, Pharm.D.&lt;br /&gt;     Center for Drug  Evaluation and Research&lt;br /&gt;     Food and Drug Administration&lt;br /&gt;     10903 New Hampshire  Avenue&lt;br /&gt;     WO31-2417&lt;br /&gt;     Silver Spring, Maryland 20993-0002&lt;br /&gt;     Phone:  301-796-9001&lt;br /&gt;     Fax: 301-847-8533&lt;br /&gt;     E-mail: &lt;a href="mailto:DODAC@fda.hhs.gov"&gt;DODAC@fda.hhs.gov&lt;/a&gt;&lt;/li&gt; &lt;/ul&gt; &lt;ul&gt;     &lt;li&gt;FDA Advisory Committee Information Line&lt;br /&gt;     1-800-741-8138&lt;br /&gt;     (301-443-0572  in the Washington DC area) - follow the prompts to the desired center or product  area&lt;br /&gt;     Please call the Information Line for up-to-date information on this  meeting.&lt;/li&gt; &lt;/ul&gt; &lt;p&gt;A notice in the Federal Register about last minute modifications that impact a previously announced advisory committee meeting cannot always be published quickly enough to provide timely notice.  Therefore, you should always check the agency&amp;rsquo;s Web site and call the FDA Advisory Committee Information Line to learn about possible modifications before coming to the meeting.&lt;/p&gt; &lt;p&gt;Persons attending FDA&amp;rsquo;s advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.  FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Yvette Waples at (301) 796-9001 at least 7 days in advance of the meeting.&lt;/p&gt; &lt;p&gt;Information regarding ground transportation, airport information, lodging, driving directions and visitor parking, and security can be accessed at: &lt;a target="" href="[!--$wcmUrl('link','UCM241740')--]"&gt;Public Meetings at the FDA White Oak Campus&lt;/a&gt;.&lt;/p&gt; &lt;p&gt;FDA is committed to the orderly conduct of its  advisory committee meetings. Please visit our Web site at &lt;a href="[!--$wcmUrl('link','UCM111462')--]" target=""&gt;Public Conduct During FDA Advisory Committee Meetings&lt;/a&gt; for procedures on public conduct  during advisory committee meetings.&lt;/p&gt; &lt;p&gt;Notice of this meeting is given under the Federal Advisory Committee Act (5  U.S.C. app.2).&lt;/p&gt;</wcm:element>
<wcm:element name="MainList1"></wcm:element>
  <wcm:element name="MainList2"></wcm:element>
  <wcm:element name="MainList3"></wcm:element>
</wcm:root>
